Visit our FAQ
Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888
Product Categories
Application
Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.
Benazepril-d5 is intended for use as an internal standard for the quantification of benazepril (Item No. 23804). Benazepril is a prodrug of the angiotensin converting enzyme (ACE) inhibitor benazeprilat (Item No. 21796).1 It is metabolized to benazeprilat by hepatic esterases. Benazepril inhibits the in vitro enzymatic activity of partially purified ACE isolated from rabbit lung (IC50 = 2 nM).2 It decreases the triglyceride and total cholesterol levels in normotensive rats when administered at a dose of 30 mg/kg and decreases aortic atherosclerosis in cholesterol-fed rabbits when administered at a dose of 3 mg/kg per day.3 Benazepril (0.1-10 mg/kg per day) reduces blood pressure in spontaneously hypertensive rats.4 It also decreases proteinuria in cats with chronic kidney disease when administered at doses ranging from 0.5 to 1 mg/kg per day.5 Formulations containing benazepril have been used to treat hypertension, congestive heart failure, and chronic kidney disease in both human and veterinary medicine.
WARNING This product is not for human or veterinary use.
1. Pharmacokinetics and pharmacokinetic/pharmacodynamic relationships for angiotensin-
2. Dual angiotensin converting enzyme/thromboxane synthase inhibitors. J. Med. Chem. 37(12), 1823-1832 (1994).
3. General pharmacology of the novel angiotensin converting enzyme inhibitor benazepril hydrochloride. Effects on cardiovascular, visceral and renal functions and on hemodynamics. Arzneimittelforschung 41(9), 913-923 (1991).
4. Synthesis and biological properties of (carboxyalkyl)amino-
5. Tolerability and efficacy of benazepril in cats with chronic kidney disease. J. Vet. Intern. Med. 20(5), 1054-1064 (2006).